Table 1.
Demographic and clinical details of current amputees
| Sex/Age, yr | Years Since Amputation | Level of Amputation | Side of Amputation | Prosthesis Use | NPS | SF-MPQ | PLP Bursts | RLP | Pain Medication |
|---|---|---|---|---|---|---|---|---|---|
| F/37 | 4 | BE | R | + | 54 | 17 | 8 | — | — |
| M/42 | 21 | AE | R | — | 58 | 22 | 10 | — | — |
| M/62 | 36 | AE | R | — | — | — | — | 5 | — |
| F/46 | 3 | BE | R | + | — | — | — | 5 | Neurontin |
| M/32 | 14 | BE | R | + | — | — | — | — | — |
| F/67 | 2 | AE | R | + | 12 | 1 | 6 | 2 | Neurontin |
| F/31 | 7 | AE | R | + | 23 | 5 | 5 | — | Tylenol, Oxycodone, Flexeril |
| F/43 | 6 | AE | R | — | 40 | 26 | 8 | — | Hydrocodone, Fentanyl patch, Cymbalta |
| M/56 | 3 | AE | R | + | 24 | 5 | 3 | — | Aleve |
| M/52 | 11 | BE | L | + | 17 | 3 | 6 | — | Citalopram |
| F/64 | 13 | AE | R | + | 25 | 0 | 6 | — | — |
| M/20 | 6 | BE | L | + | 16 | 2 | 9 | — | — |
| F/38 | 38 | BE | L | — | — | — | — | 2 | Klonopin |
| M/29 | 7 | BE | R | + | 22 | 11 | 10 | — | — |
| M/65 | 45 | BE | R | + | 14 | 4 | 9 | — | Aleve |
| M/44 | 5 | AE | R | + | 53 | 18 | 10 | 4 | — |
| M/42 | 20 | BE | L | + | 51 | 19 | 10 | — | — |
| M/74 | 8 | BE | R | + | — | — | — | 7 | Neurotin |
| F/22 | 2 | AE | R | + | 19 | 4 | 9 | — | — |
F, female; M, male; L, left; R, right; AE, above elbow; BE, below elbow; PLP, phantom limb pain; RLP, residual limb pain; NPS, Neuropathic Pain Scale; SF-MPQ, short-form McGill Pain Questionnaire. PLP bursts and RLP were evaluated on a scale ranging from 0 = no pain to 10 = severe pain.